Approval · Notice of Compliance 31925 · 2023
IPG-GABAPENTIN: Notice of Compliance 31925
Issued October 23, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31925
- Date
- October 23, 2023
- Company
- Marcan Pharmaceuticals Inc.Ottawa, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph. Update to Labels to align with Plain Language Labelling (PLL) regulations
- Canadian reference product
- NEURONTIN (Pfizer Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| IPG-GABAPENTIN | Not yet assigned | — |
Medicinal ingredients
- GABAPENTIN 100 MG per CAP
- GABAPENTIN 300 MG per CAP
- GABAPENTIN 400 MG per CAP